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Host immunosurveillance as a mechanism to promote
tumor growth or to suppress tumor development is well
studied. It is less known how immuno-selective pressure
in the form of immunotherapies can instruct the
immune system during this process. We hypothesized
that the application of a T cell-dependent selection pres-
sure in the form of a whole tumor vaccine would alter
the immunogenic architecture in our transplantable
murine melanoma model SB-3123, and generated an
escape variant to test this hypothesis.
We performed whole-exome and RNA-sequencing of
the tumor line SB-3123 and two fresh tumors generated
by subcutaneous implantation of SB-3123 to identify
mutations and to assess levels of expression. There were
349 mutations shared between the tumor line and fresh
tumors, with less than 5 mutations that were unique to
each sample. We then determined the stability of these
mutations and created a re-derived tissue culture line
from a fresh SB-3123 tumor. Remarkably, the re-derived
tissue culture line retained 333 mutations in common
with the prior samples and produced only 2 unique
mutations.
To test the immunogenicity of SB-3123, we vaccinated
mice with irradiated SB-3123 and administered a live
tumor challenge two weeks after vaccination. This
resulted in a profound vaccination response and mice
were completely protected from tumor for over 200 days.
Surprisingly, one vaccinated mouse developed a recru-
desced tumor at the site of implantation 40 days after
challenge, and a tumor line was created (SB-3123-esc).
We asked whether SB-3123-esc represented an antigen
escape variant by immunizing mice with SB-3123 and
challenging with either SB-3123 or SB-3123-esc. Vaccina-
tion with SB-3123 did not protect against SB-3123-esc.
We also performed sequencing on SB-3123-esc and
determined that no known genes involved in antigen pro-
cessing and presentation were mutated, and SB-3123-esc
upregulated class I molecules at similar levels compared
to SB-3123 upon IFN-g treatment.
Our most striking results were the differences in muta-
tional constituents between SB-3123 and SB-3123-esc. Of
the nonsynonymous mutations called in the coding region,
441 were common to both tumor lines while 80 were
unique to SB-3123 and 40 to SB-3123-esc. Furthermore,
we were able to determine that SB-3123-esc lost 2 immu-
nogenic neoantigens but had acquired 5. Future investiga-
tions are directed towards identifying the rejection antigen
responsible for the escape phenotype of SB-3123-esc.
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